Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Multiple Sclerosis (MS) as defined by revised McDonald criteria.
A relapsing-remitting course of disease with at least 1 documented relapse during the previous year, or 2 documented relapses during the previous 2 years, or a positive gadolinium (Gd)-enhanced MRI scan at screening (in case the first MRI scan obtained at screening is negative, a second scan may be obtained 1 month later.)
An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at randomization.
Neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization.
Patients who decline initiation or continuation of treatment with available disease modifying drugs for MS, for whatever reason, after having been informed about their respective benefits and possible adverse events by the investigator.
You may not be if
A manifestation of another type of MS than RRMS
History of chronic disease of the immune system other than MS
Malignancies, diabetes, significant cardiovascular, pulmonary and hepatic diseases and conditions
Active infections
Clareo Health | Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
